Omni Biotech Innovations is an early‑stage drug discovery company developing differentiated bispecific and multispecific antibodies for autoimmune diseases, where existing therapies have low remission rates and significant side effects.
Funding
Funding not disclosed
Founders
Product
Problem
Current therapies for autoimmune diseases often achieve low remission rates and are associated with significant side effects, leaving many patients without effective treatment options.
Solution
Omni Biotech Innovations focuses on discovering and developing differentiated bispecific and multispecific antibody therapeutics specifically for autoimmune disorders. By leveraging advanced antibody engineering techniques within a 16,000 sq ft state‑of‑the‑art facility, the company creates novel antibody formats that can simultaneously engage multiple disease‑relevant targets. This approach aims to enhance therapeutic efficacy while reducing adverse effects compared to existing monotherapy antibodies. The pipeline targets high‑prevalence autoimmune conditions with substantial unmet medical needs, seeking to deliver safer, more effective medicines to patients.
Target Audience
Primary customers are pharmaceutical partners and biotech companies seeking novel antibody candidates for autoimmune disease programs, as well as clinical research organizations conducting preclinical and early‑stage trials.
Features
- Bispecific and multispecific antibody platforms designed to modulate multiple immune pathways concurrently
- Proprietary engineering workflows that enable rapid generation and optimization of complex antibody formats
- Integrated discovery-to-preclinical pipeline housed in a dedicated 16,000 sq ft facility for end‑to‑end development
- Emphasis on under‑explored antibody architectures to address gaps left by conventional therapies
- Preclinical models tailored to evaluate efficacy and safety in autoimmune disease contexts